Essex Bio-Technology Limited reported the repurchase of 71,000 ordinary shares on 22 June 2026 via on-market transactions on the Hong Kong Stock Exchange.

• Transaction details: Purchase prices ranged between HKD 2.62 and HKD 2.64, resulting in a total outlay of HKD 0.19 million. The volume equates to 0.0125% of the company’s issued share capital (excluding treasury shares) prior to the buyback.

• Treasury shares: All repurchased shares have been retained as treasury stock, lifting the treasury-share balance from 135,000 to 206,000.

• Share capital movement: – Opening balance on 18 June 2026: 566.87 million issued shares (excluding treasury shares). – Post-repurchase balance on 22 June 2026: 566.80 million issued shares (excluding treasury shares). – Total issued shares, including treasury stock, remains unchanged at 567.01 million.

• Repurchase mandate: The share buyback forms part of the mandate granted on 26 May 2026, which authorises Essex Bio-Technology to repurchase up to 56.70 million shares. Cumulative purchases under this mandate now stand at 206,000 shares, representing 0.0363% of the issued share base as of the mandate date.

• Moratorium: In accordance with Hong Kong listing rules, Essex Bio-Technology is restricted from issuing new shares or disposing of treasury shares until 22 July 2026.

The board confirmed that the repurchase complied with all relevant regulatory requirements and that funding for the transaction has been duly settled.